Cargando…

Chitosan-based nanoparticles with damnacanthal suppress CRM1 expression

Cancer is one of the leading causes of mortality worldwide. Phytochemicals may be promising anticancer agents given their various chemical structures and diverse biological activities. Damnacanthal (DAM) is a major bioactive component of Noni, which has been investigated previously as a cancer-preve...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaichanasak, Nadda, Rojanapanthu, Pleumchitt, Yoon, Yongdae, Gritsanapan, Wandee, Chirachanchai, Suwabun, Sathirakul, Korbtham, Nualsanit, Thararat, Seong, Je Kyung, Baek, Seung Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256335/
https://www.ncbi.nlm.nih.gov/pubmed/30546436
http://dx.doi.org/10.3892/ol.2018.9507
Descripción
Sumario:Cancer is one of the leading causes of mortality worldwide. Phytochemicals may be promising anticancer agents given their various chemical structures and diverse biological activities. Damnacanthal (DAM) is a major bioactive component of Noni, which has been investigated previously as a cancer-preventive or chemotherapeutic agent. DAM has also been reported to exhibit anti-proliferative activity in several cancer types. In the present study, it was identified that DAM downregulates chromosome maintenance protein 1 (CRM1) expression in human cancer cells. The application of chitosan-based nanoparticles (NPs) with DAM also induced CRM1 downregulation, which suggests that chitosan-based NPs may be effective vehicles for delivery of phytochemicals such as DAM. It was also identified that DAM increased the levels of the tumor suppressor non-steroidal anti-inflammatory drugs-activated gene 1 in the nucleus, thereby leading to enhanced anticancer effects. The results of the present study indicate that DAM and its nanoformulation may be a candidate anticancer drug.